Lanean...
A phase II study of sorafenib in malignant mesothelioma: results of CALGB 30307
HYPOTHESIS: Malignant mesotheliomas (MM) express VEGFR, PDGFR, and cKIT. Sorafenib is a potent inhibitor of the RAS/RAF/MEK pathway and also targets VEGFR and cKIT. We evaluated the activity of sorafenib in patients with unresectable mesothelioma. METHODS: MM patients who had received 0 to 1 prior c...
Gorde:
| Egile Nagusiak: | , , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2010
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3823555/ https://ncbi.nlm.nih.gov/pubmed/20736856 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e3181ec18db |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|